Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

COPD-OMA - Clinical Trial

¿Cuál es el Propósito de este estudio?

The treatment will last for 12 months. People in the study will get shots of a medicine called omalizumab. Some will get the shots every month, and others will get them every two weeks. At each visit, they will answer questions on forms. Blood will be taken at the first visit and the last visit.

¿Cuál es la Condición que se está estudiando?

Chronic Obstructive Pulmonary Disease (COPD)

¿Quién puede participar en el Estudio?

People in this study must be at least 40 years old and have smoked for more than 10 years. They need to have a lung disease called COPD and already be using certain inhaled medicines. They must have a high score on a breathing test or have had at least one bad flare-up in the past year. Women who can have babies must have a negative pregnancy test before starting, and both men and women must agree to use birth control during the study. Their lung test results must show reduced breathing ability. They also need to have an allergy to things like cats, dogs, mice, cockroaches, or dust mites, and still be exposed to that allergen at home.

Grupo etario
Adultos

¿Qué Implica?

The goal of this study is to find out if shots of a medicine called omalizumab, also known as Xolair, can lower the number of times people have bad flare-ups of their illness each year.

Detalles del Estudio

Título Completo
Clinical Trials of Omalizumab for Allergen Sensitized and Exposed Individuals with COPD
Investigador Principal
Loretta G. Que, MD
Especialista en neumología
Número de Protocolo
IRB: PRO00119272
NCT: NCT07059091
Fase
Phase II
ClinicalTrials.gov
Estado de inscripción
Pronto disponible para inscripción
Apoye la investigación de Duke Health o rinda homenaje a un ser querido con un regalo conmemorativo.
Contribuya a Duke Health